AbbVie, Calico Extend Their Collaboration On Aging
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
You may also be interested in...
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.